Beta-glycosidase SS-BGL mutant for modifying ginsenoside and application thereof
US12258598B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 18, 2024 |
| Grant date | Mar 25, 2025 |
| Priority date | — |
| Expiry date | Apr 18, 2044 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
A β-glycosidase SS-BGL mutant for modifying ginsenoside and application thereof are provided, which relate to the field of genetic engineering technologies. The β-glycosidase SS-BGL mutant is β-glycosidase SS-BGL with the amino acid sequence as shown in SEQ ID NO: 1 having mutation at one or more sites. A single-site mutation includes: A1, making glutamine at 96th position of SEQ ID NO: 1 to be mutated to glutamic acid; A2, making asparagine at 97th position of SEQ ID NO: 1 to be mutated to aspartate; A3, making asparagine at 128th position of SEQ ID NO: 1 to be mutated to aspartate; A4, making asparagine at 302th position of SEQ ID NO: 1 to be mutated to aspartate. A double-site mutation is a combination of A3 and A4, a three-site mutation is a combination of A1, A2 and A4, and a four-site mutation is a combination of A1, A2, A3 and A4.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.